CA46 Cells

The CA46 cell line is a human cell line derived from a Burkitt’s lymphoma, which is a type of non-Hodgkin’s lymphoma. This cell line exhibits characteristics typical of a transformed B lymphocyte lineage and was originally established from the malignant cells of a 39-year-old male. CA46 cells are noteworthy for their study in oncology research, particularly in understanding the Epstein-Barr virus (EBV) negative Burkitt’s lymphoma pathogenesis and the underlying molecular biology of B-cell differentiation and transformation.

Scientifically, CA46 cells have been instrumental in the study of gene expression related to B-cell development and malignancy. They are EBV-negative, which allows researchers to investigate tumor characteristics and behaviors without the influence of EBV, a common confounder in many lymphoid malignancies. The cell line also provides a useful tool for examining the efficacy of therapeutic agents and the mechanisms of drug resistance in lymphoma, contributing to the development of targeted therapies in hematologic cancers.

In research settings, CA46 cells have been used to assess cytotoxic responses to chemotherapeutic agents and to explore signal transduction pathways involved in B-cell proliferation and apoptosis. Their genomic stability and susceptibility to genetic manipulation further enable their use in molecular biology and genetic studies related to cancer research and therapy development.